Notably, over 60% of patients with malignant gliomas had at least a 50% reduction in tumor volume following the treatment of Tf-CRM107 due to the active targeting ability of Tf [59], indicating the clinical effectiveness of CED administration of functionalized proteins/peptides. The gene discussed is TF; the disease is malignant glioma.